用于预测或诊断抑郁症复发的标志物组合及其应用

• Format: Patent
• Language: Chinese
• Published: 03.05.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

本发明提供了用于预测或诊断抑郁症复发的标志物组合及其应用，具体地，本发明提供了检测来自检测对象的样品中HSP90，HIF-1α，BICC1基因和蛋白水平的试剂材料和/或仪器设备在制备用于诊断抑郁症复发风险的检测设备中的应用。单独或联合使用HSP90、HIF-1α、BICC1蛋白，HSP90、BICC1的转录本作为外周血液生物标记物检测其含量用于预测和诊断抑郁症复发，可显著提高抑郁症首发与复发的鉴别诊断准确性，检测方法更方便快速，患者依从性高，有助于解决抑郁症早期预警和复发诊断困难的问题。本发明的抑郁症复发风险标志物可作为诊断抑郁症复发和评价抑郁症复发治疗效果的标记物，具有高灵敏度和特异性等优点。 The present invention provides a marker combination for predicting or diagnosing depression recurrence and use thereof. Specifically, the present invention provides use of a reagent material and/or a device for detecting gene and protein levels of HSP90, HIF-1α, and BICC1 in a sample from a subject in preparing a detection device for diagnosing depression recurrence. Use of HSP90, HIF-1α or BICC1 protein, or HSP90 or BICC1 transcripts alone or in combination as peripheral blood biomarkers and the content assay of the biomarkers for predicting and diagnosing depression recurrence, can improve the diagnostic accuracy for differentiating first-onset and recurrent depressions. The method features convenience and effi